Our results demonstrate the novel action mechanism of E2 in OCs to impair cytoskeletal reorganization in a non-genomic way, suggesting that SHP2 or NOX1 could be a potential therapeutic target for osteoporosis upon loss of ovarian function. This evidence concerns the gene NOX1 and osteoporosis.